FindTrial
Sign In

Does medication help reduce incidence of High Altitude Pulmonary Edema

Proof of Concept Study- Does Tadalafil and / or Acetazolamide help reduce incidence of HAPE: A hospital based randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/03/041543
Enrollment
100
Registered
2022-03-31
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J988- Other specified respiratory disorders

Interventions

Intervention1: Tab Nifedipine: Tab Nifedipine 30 mg SR BD pre-induction till 3 days at High Altitude Intervention2: Tab Tadalafil: Tab Tadalafil 10 mg BD pre-induction till 3 days at High Altitude Int

Sponsors

Office of the DGAFMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically and Radiologically confirmed cases of HAPE

Exclusion criteria

Exclusion criteria: 1) Concomitant HACE 2) Patients with HTN, IHD, DM, COPD 3) Known allergy to Supha drugs (Acetazolamide)

Design outcomes

Primary

MeasureTime frame
HAPE in patients - clinicallyTimepoint: After 4 weeks sick leave again on Reinduction to High Altitude—

Secondary

MeasureTime frame
Recurrence of HAPETimepoint: BASELINE AND After 1 month HAPE—

Countries

India

Contacts

Public ContactDr Oommen Savina George

Armed Forces Medical Services, previously MUHS NASHIK

savinaoommen@gmail.com9773788807

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 10, 2026